Skip to main content

Table 2 Antidiabetic drugs prior to administration of DPP-4 inhibitors

From: Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus

Antidiabetic drugsSitagliptinVildagliptinTeneligliptinAlogliptinLinagliptin
Insulin145 (16.5%)26 (10.3%)55 (21.2%)8 (3.4%)30 (16.7%)
Sulphonylurea333 (37.9%)69 (27.3%)36 (13.9%)71 (30%)30 (16.7%)
Biguanide275 (31.3%)63 (24.9%)36 (13.9%)49 (20.7%)34 (18.9%)
Alpha-glucosidase inhibitor189 (21.5%)43 (17%)22 (8.5%)46 (19.4%)15 (8.3%)
Thiazolidinedione102 (11.6%)21 (8.3%)7 (2.7%)51 (21.5%)4 (2.2%)
Glinide75 (8.5%)21 (8.3%)10 (3.9%)11 (4.6%)15 (8.3%)
SGLT2 inhibitor5 (0.6%)2 (0.8%)10 (3.9%)0 (0%)3 (1.7%)
Nothing251 (28.6%)99 (39.1%)145 (55.8%)93 (39.2%)89 (49.4%)
  1. DPP-4 dipeptidyl-peptidase 4, SGLT2 sodium glucose co-transporter 2